EP Patent

EP2386302A1 — A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof

Assigned to Ranbaxy Laboratories Ltd · Expires 2011-11-16 · 15y expired

What this patent protects

A controlled release pharmaceutical dosage forms of trimetazidine and the process of preparation thereof, suitable for once-daily dosing is disclosed. The controlled release pharmaceutical dosage form of trimetazidine comprises trimetazidine or its pharmaceutically acceptable sal…

USPTO Abstract

A controlled release pharmaceutical dosage forms of trimetazidine and the process of preparation thereof, suitable for once-daily dosing is disclosed. The controlled release pharmaceutical dosage form of trimetazidine comprises trimetazidine or its pharmaceutically acceptable salts; one or more gel-forming materials; and one or more gas generating materials.

Drugs covered by this patent

Patent Metadata

Patent number
EP2386302A1
Jurisdiction
EP
Classification
Expires
2011-11-16
Drug substance claim
No
Drug product claim
No
Assignee
Ranbaxy Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.